Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six Months


Por: Sancho-Saldaña, A, Gil-Sánchez, A, Quirant-Sánchez, B, Boigues, M, Canudes, M, Peralta, S, Solana, MJ, González-Mingot, C, Quibus, L, Martínez-Cáceres, E, Torres, P, Hervás, JV, Moreno-Magallon, J and Brieva, L

Publicada: 26 may 2025
Resumen:
Background: Patients with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) may exhibit altered immune responses to infections such as SARS-CoV-2. This study aimed to characterize the cytokine profiles associated with prior SARS-CoV-2 infection and to identify immune markers related to the persistence of the humoral response in pwMS. Methods: A total of 90 pwMS were recruited before the introduction of COVID-19 vaccination in Spain; 46 were seropositive-defined by the presence of IgG, IgM, or IgA antibodies against SARS-CoV-2-and 44 were seronegative. We compared baseline cytokine levels between groups and followed seropositive individuals for six months to assess IgG antibody persistence. Results: Seropositive patients showed significantly lower baseline levels of IL-10, IL-23, and IFN-alpha compared to seronegative individuals. Notably, elevated IL-18 at baseline was associated with persistent IgG seropositivity at six months. Conclusions: These findings suggest a distinct cytokine profile in SARS-CoV-2-exposed pwMS and highlight IL-18 as a potential marker of sustained humoral response. This study provides insight into host-virus immune dynamics in MS patients and may help guide future strategies for infection monitoring and immune evaluation in this population.

Filiaciones:
Sancho-Saldaña, A:
 Hosp Arnau Vilanova, Serv Neurol, Lleida 25198, Spain

 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

Gil-Sánchez, A:
 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

:
 Hosp Univ Germans Trias i Pujol, Germans Trias i Pujol Univ Hosp & Res Inst, Immunol Div, Badalona 08916, Spain

 Autonomous Univ Barcelona, Dept Cell Biol Physiol Immunol, Cerdanyola Del Valles 08193, Spain

Boigues, M:
 Hosp Univ Germans Trias i Pujol, Germans Trias i Pujol Univ Hosp & Res Inst, Immunol Div, Badalona 08916, Spain

Canudes, M:
 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

Peralta, S:
 Hosp Arnau Vilanova, Serv Neurol, Lleida 25198, Spain

 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

Solana, MJ:
 Hosp Arnau Vilanova, Serv Neurol, Lleida 25198, Spain

 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

González-Mingot, C:
 Hosp Arnau Vilanova, Serv Neurol, Lleida 25198, Spain

 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

 Univ Lleida UdL, Dept Med, Lleida 25198, Spain

Quibus, L:
 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

:
 Hosp Univ Germans Trias i Pujol, Germans Trias i Pujol Univ Hosp & Res Inst, Immunol Div, Badalona 08916, Spain

 Autonomous Univ Barcelona, Dept Cell Biol Physiol Immunol, Cerdanyola Del Valles 08193, Spain

Torres, P:
 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

 Univ Lleida UdL, Lleida Biomed Res Inst IRBLleida, Dept Expt Med, Metab Pathophysiol Res Grp, Lleida 25198, Spain

Hervás, JV:
 Hosp Sant Joan Despi Moises Broggi, Serv Neurol, Barcelona 08970, Spain

Moreno-Magallon, J:
 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

Brieva, L:
 Hosp Arnau Vilanova, Serv Neurol, Lleida 25198, Spain

 Inst Recerca Biomed Lleida IRBLleida, Serv Neuroinmunol, Lleida 25198, Spain

 Univ Lleida UdL, Dept Med, Lleida 25198, Spain
ISSN: 20770383





Journal of Clinical Medicine
Editorial
MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 14 Número: 11
Páginas:
WOS Id: 001505649000001
ID de PubMed: 40507498
imagen Green Submitted, gold

MÉTRICAS